Airway inflammation and mannitol challenge test in COPD.

Area of Science:

• Pulmonary Medicine
• Respiratory Research
• Clinical Trials

Background:

• Eosinophilic airway inflammation is a target for anti-inflammatory therapy in Chronic Obstructive Pulmonary Disease (COPD).
• Airway hyperresponsiveness (AHR) measured by indirect challenges is linked to airway inflammation.
• This study investigated if AHR to inhaled mannitol reflects eosinophilia in induced sputum of COPD patients.

Purpose of the Study:

• To determine if airway hyperresponsiveness to inhaled mannitol correlates with eosinophilic airway inflammation in COPD.
• To assess the utility of mannitol challenge in identifying eosinophilic airway inflammation for personalized COPD treatment.

Main Methods:

• Twenty-eight mild-moderate COPD patients underwent mannitol challenge and hypertonic saline-induced sputum collection.
• Airway hyperresponsiveness to mannitol was quantified as response-dose-ratio (RDR).
• RDR was correlated with sputum biomarkers including eosinophil counts, Eosinophil Cationic Protein (ECP), Myeloperoxidase (MPO), and Interleukin-8 (IL-8).

Main Results:

• A positive correlation was observed between RDR to mannitol and eosinophil numbers and IL-8 levels in hypertonic saline-induced sputum.
• Significant correlations were found between RDR and eosinophils, ECP, IL-8, and MPO in sputum collected post-mannitol challenge.
• Receiver Operating Characteristic (ROC) curves indicated 60% sensitivity and 100% specificity of RDR for detecting >2.5% eosinophils in mannitol-induced sputum.

Conclusions:

• Mannitol hyperresponsiveness in mild-moderate COPD is associated with airway inflammation biomarkers.
• The high specificity of the mannitol challenge suggests its suitability for excluding eosinophilic airway inflammation.
• This test may facilitate individualized treatment strategies for COPD patients.